Absci Corp

Listed Company

ABSICIK 0001672688NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthServices-Commercial Physical & Biological ResearchFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-115.18M

Total Assets

$216.30M

Equity

$189.45M

Shares Out

153.02M

Op. Cash Flow

$-92.92M

Business

Absci Corp is a data-first generative AI drug creation company that designs differentiated antibody therapeutics using an Integrated Drug Creation platform. It offers AI-driven de novo antibody design, multi-parameter lead optimization, synthetic-biology data generation (SoluPro, ACE assays), and high-throughput wet-lab validation to produce and validate antibody candidates. Its business is organized around internally developed programs, partnered drug creation programs, and co-development collaborations that leverage its lab-in-the-loop platform. Absci distributes its services and programs through collaborations, licensing and partnerships with pharmaceutical, biotechnology and academic partners in the United States and internationally.

Summary from filing dated 2025-03-18

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Partner program revenue	3	5	6	5	4
Research and development	81	64	48	59	45
Selling, general and administrative	35	36	38	41	29
Depreciation and amortization	12	13	14	13	7
Gain on settlement of contingent consideration	−5	0	—	—	—
Total operating expenses	123	113	121	112	80
Operating loss	−120	−109	−116	−107	−75
Interest expense	−209,000	−565,000	−1	—	—
Other income, net	5	6	6	2	−31
Total other income, net	5	6	5	1	−35
Loss before income taxes	−115	−103	−110	−105	−110
Income tax expense	−69,000	−70,000	−100,000	461,000	9
Net loss	−115	−103	−111	−105	−101
Net loss per share: basic (in usd per share)	−0.84	−0.94	−1.2	−1.15	−2.08
Net loss per share: diluted (in usd per share)	−0.84	−0.94	−1.2	−1.15	−2.08
Weighted-average common shares outstanding: basic (in shares)	137	110	92	91	50
Weighted-average common shares outstanding: diluted (in shares)	137	110	92	91	50
Foreign currency translation adjustments	448,000	−26,000	40,000	−66,000	−13,000
Unrealized gain on marketable securities	147,000	59,000	43,000	−41,000	0
Comprehensive loss	−115	−103	−110	−105	−101

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	20	41	72	60	253
Restricted cash	0	16	16	15	11
Marketable securities	124	71	—	—	—
Prepaid expenses and other current assets	5	5	5	6	9
Total current assets	150	134	121	187	273
Operating lease right-of-use assets	3	4	4	5	7
Property and equipment, net	21	29	41	53	52
Intangibles, net	42	45	48	52	55
Restricted cash, long-term	1	1	1	2	17
Other long-term assets	383,000	705,000	2	1	1
TOTAL ASSETS	216	214	217	321	426
Accounts payable and accrued expenses	19	10	—	—	—
Contingent consideration	0	13	13	—	—
Long-term debt	873,000	3	3	3	2
Operating lease obligations	2	2	2	2	2
Deferred revenue	739,000	1	3	445,000	1
Total current liabilities	23	29	30	30	34
Long-term debt, net of current portion	0	1	5	8	1
Operating lease obligations, net of current portion	3	4	6	7	9
Deferred revenue, long-term	436,000	0	966,000	0	—
Other long-term liabilities	1	133,000	295,000	35,000	12
TOTAL LIABILITIES	27	34	41	47	60
Commitments (See Note 11)	—	—	—	—	—
Preferred stock	0	0	0	0	0
Common stock	15,000	12,000	9,000	9,000	9,000
Additional paid-in capital	814	689	583	570	557
Accumulated deficit	−625	−510	−406	−296	−191
Accumulated other comprehensive income (loss)	591,000	−4,000	−37,000	−120,000	−13,000
TOTAL STOCKHOLDERS' EQUITY	189	179	176	274	366
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	216	214	217	321	426

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation	18	19	11	13	11
Accretion of discount on marketable securities	−3	−4	−3	−688,000	0
Gain on settlement of contingent consideration	−5	0	—	—	—
Other	−584,000	2	334,000	721,000	301,000
Accounts receivable, net	0	2	−666,000	—	—
Prepaid expenses and other current assets	−424,000	−484,000	2	2	−8
Operating lease right-of-use assets and liabilities	−555,000	−762,000	−856,000	−640,000	3
Other long-term assets	249,000	−68,000	−255,000	13,000	126,000
Accounts payable and accrued expenses	1	2	−786,000	−533,000	2
Deferred revenue	59,000	−3	4	−907,000	−1
Net cash used in operating activities	−93	−72	−65	−81	−61
Purchases of property and equipment	−1	−404,000	−860,000	−16	−38
Investment in marketable securities	−120	−186	−147	−109	0
Proceeds from maturities of marketable securities	70	144	230	5	0
Proceeds from sales of property and equipment	1	939,000	254,000	133,000	0
Net cash used in investing activities	−50	−42	82	−127	−67
Principal payments on long-term debt	−3	−3	−3	−5	−2
Principal payments on finance lease obligations	−79,000	−643,000	−2	−3	−3
Proceeds from issuance of common stock, net	106	82	862,000	656,000	210
Proceeds from issuance of common stock through employee equity plans, net	3	4	862,000	—	—
Net cash provided by financing activities	106	83	−4	5	336
Net decrease in cash, cash equivalents, and restricted cash	−37	−31	13	−203	208
Cash paid during the period for interest	178,000	561,000	970,000	895,000	652,000
Right-of-use assets obtained in exchange for operating lease obligation	0	433,000	0	111,000	3
Payments on long-term debt by third-party through sale of equipment	0	540,000	0	123,000	6

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro